The table below shows Xenon Pharmaceuticals Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$279.12M
-$181.39M
-$151.11M
-$101.03M
-$69.50M
-$48.12M
Capital expenditure
$799.00K
$3.08M
$5.62M
$2.89M
$2.05M
$2.64M
Investing cash flow
$218.00M
$165.00M
-$111.39M
-$293.40M
-$246.77M
-$16.82M
Dividends paid
-
-
-
-
XENE operating cash flow (10-K history)
Xenon Pharmaceuticals Inc. reported operating cash flow of -$279.12M for fiscal year 2025. That is down 53.9% from -$181.39M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$28.73M (FY 2017) to -$279.12M. Figures come from the company's audited annual reports as filed with the SEC.